IL18: Interleukin-18
Pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses.
- Drugs that act on it: 3
- Approved: 0
- In phases 1 to 3: 3
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on IL18, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
- Other 2
| Tadekinig alfa | Phase 3 | AB2 Bio Ltd. | Other | InhibitorInterleukin-18 inhibitor | 1 |
| GSK-1070806 | Phase 2 | GSK | Other | InhibitorInterleukin-18 inhibitor | 2 |
| Camoteskimab | Phase 2 | Apollo Therapeutics Ltd | Antibody | Cross-linking agentInterleukin-18 cross-linking agent | 1 |
| A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis | GSK-1070806 | Phase 1 | Recruiting | GlaxoSmithKline | Aug 5, 2026 |
| A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative Colitis | GSK-1070806 | Phase 1 | Recruiting | GlaxoSmithKline | Aug 5, 2026 |
| A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis | Camoteskimab | Phase 2 | Recruiting | Apollo Therapeutics Ltd | May 20, 2026 |
| Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome | Tadekinig alfa | Early phase 1 | Recruiting | University of Pennsylvania | Mar 31, 2022 |
- Hemophagocytic syndrome0.28
- Osteoporosis0.15
- Atopic eczema0.14
- Adult-onset Still disease0.14
- Bile duct disorder0.13
- Type 2 diabetes mellitus0.13
- Systemic lupus erythematosus0.13
- Rheumatoid arthritis0.12
- Chronic obstructive pulmonary disease0.12
- Neoplasm0.12
- Acute kidney injury0.12
- Smoking initiation0.12
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1741305, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q14116, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets